Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02058277 · ClinicalTrials.gov registry record · Phase 1

A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers

A Phase 1 study, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target

NCT02058277: Completed Phase 1 study, sponsored by Pfizer.

NCT02058277 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02058277, a Phase 1 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target

Study Summary

This is an open label, randomized, single dose, one cohort, two sequence, two period crossover study in healthy subjects. The primary objective of the study is to evaluate the effect of a single oral dose of aprepitant on the pharmacokinetic (PK) profile of a single oral dose of bosutinib in healthy subjects.

Primary Outcome

AUC is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption.

Interventions

  • DRUG bosutinib or bosutinib + aprepitant

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2014-05
Est. Completion 2014-06
Phase Phase 1
Pfizer

1,845 total trials

What the finished NCT02058277 record still lists

NCT02058277 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).

The record links to 0 conditions, and to 1 intervention - of which bosutinib or bosutinib + aprepitant is the first listed.

NCT02058277 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02058277 about?

NCT02058277 is a clinical study titled "A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers". This is an open label, randomized, single dose, one cohort, two sequence, two period crossover study in healthy subjects. The primary objective of the study is to evaluate the effect of a single oral dose of aprepitant on the pharmacokinetic (PK) profile of a single oral dose of bosutinib in healthy...

What is the current status of trial NCT02058277?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2014-05. Estimated completion is 2014-06.

What interventions are being tested in trial NCT02058277?

The interventions under investigation include: bosutinib or bosutinib + aprepitant (DRUG).

Who is sponsoring clinical trial NCT02058277?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02058277's enrollment target sits among peer trials

20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02058277, the US trial registry maintained by the National Library of Medicine. NCT02058277 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.